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Purpose: To evaluate the clinical manifestations and causative drugs 
associated with adverse drug reactions (ADRs) spontaneously reported 
by community pharmacists and to compare the ADRs by age. 
Methods: ADRs reported to the Regional Pharmacovigilance Center of 
the Korean Pharmaceutical Association by community pharmacists 
from January 2013 to June 2014 were included. Causality was assessed 
using the WHO-Uppsala Monitoring Centre system. The patient 
population was classified into three age groups. We analyzed 31,398 
(74.9%) ADRs from 9,705 patients, identified as having a causal 
relationship, from a total pool of 41,930 ADRs from 9,873 patients. 
Median patient age was 58.0 years; 66.9% were female. 
Results: Gastrointestinal system (34.4%), nervous system (14.4%), and 
psychiatric (12.1%) disorders were the most frequent symptoms. 
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Prevalent causative drugs were those for acid-related disorders (11.4%), 
anti-inflammatory products (10.5%), analgesics (7.2%), and 
antibacterials (7.1%). Comparisons by age revealed diarrhea and 
antibacterials to be most commonly associated with ADRs in children 
(p < 0.001), whereas dizziness was prevalent in the elderly (p < 0.001). 
Anaphylactic reaction was the most frequent serious event (19.7%), 
mainly associated with cephalosporins and non-steroidal anti-
inflammatory drugs. Among 612 ADRs caused by nonprescription 
drugs, the leading symptoms and causative drugs were skin disorders 
(29.6%) and non-steroidal anti-inflammatory drugs (16.2%), 
respectively. 
Conclusions: According to the community pharmacist reports, the 
leading clinical manifestations and causative drugs associated with 
ADRs in outpatients differed among age groups. 
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An adverse drug reaction (ADR), as defined by the World Health 
Organization (WHO), is “a noxious and unintended response of a drug, 
which occurs at a dose normally used in humans for prophylaxis, 
diagnosis, or therapy” [1]. Previous reports have suggested that 7–11.2% 
of ADRs result in hospitalization [2,3] and that the mean cost of ADRs 
leading to admission was 2721 Euros per patient [4]. Previous studies 
on ADRs have focused on inpatient care settings. While hospitalized 
patients are under close medical monitoring, outpatients are not. 
Because the contact is intermittent and consultation hours are 
constrained, it is difficult for physicians to secure sufficient 
communication time to ascertain the presence of ADRs in ambulatory 
care settings. Thus, the risk and expense of treatment of ADRs in 
outpatients may increase because remedial action is often delayed [5]. 
Considering the large proportion of prescriptions issued in ambulatory 
care, knowledge of ADRs in this population is important to prevent 
medication-related harm. 
In outpatients, community pharmacists (CPs) may effectively 
monitor patient safety and provide adequate information through 
medication counseling [6,7]. It is easy for patients to visit community 
pharmacies because of their wide geographical distribution and 
accessibility without the need for an appointment. As CPs serve 
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patients with and without prescriptions, their active involvement in 
ADR monitoring and reporting is likely to improve the scope and 
quality of spontaneous ADR reporting [8].  
In 2013, the Korea Institute of Drug Safety and Risk Management 
(KIDS) added the regional pharmacovigilance center of the Korean 
Pharmaceutical Association (RPVC-KPA), to existing RPVCs. While 
the existing RPVCs targeted each regional hub and their ADR reporting 
was mainly centered on inpatients in affiliated hospitals [9], the activity 
of RPVC-KPA was conducted on a national scale and focused on 
outpatients in community pharmacies nationwide. All CPs can report 
ADRs to RPVC-KPA through the spontaneous reporting system 
connected to their pharmacy’s billing program or the KIDS website. 
Participating community pharmacies comprised 4.0% of the 20,971 
registered nationwide community pharmacies in Korea as of March 
2014 [10]. The reports by CPs comprised 3.4% of all ADR reports sent 
to KIDS by healthcare professionals [10]. This is a relatively low 
proportion in comparison to that in Netherlands, Spain, or Portugal, but 
it is comparable to the proportion in the UK, France, and Japan [11]. 
Considering the increase in the proportion of ADR reports by CPs from 
0.8% (324 reports) in the first quarter of 2013 to 10.7% (5621 reports) 
in the second quarter of 2014, the participation of CPs in ADR 
３ 
 
reporting is expected to expand [10]. Pharmacovigilance in outpatients 
can be improved by the active participation of CPs. 
Although the data from spontaneous ADR reports by CPs may 
provide more pertinent information for ambulatory patients [12], few 
studies have been reported on this topic [8]. In addition, few studies 
have compared the ADR patterns by age group in ambulatory care 
patients [13]. A systematic review for the ADRs in ambulatory care 
showed that most studies investigated ADRs leading to hospitalization 
or emergency department visit [14]. Therefore, we aimed to evaluate 
the clinical manifestations and causative drugs associated with ADRs 













ADRs spontaneously reported to RPC-KPA by CPs nationwide from 
January 2013 to June 2014 were collected. According to the WHO 
definition, this study only included ADRs associated with a dose 
normally used in humans and reports associated with a drug 
administered for ordinary prophylactic or therapeutic purposes. Reports 
related to drug abuse, suicide attempts, or medication errors were 
excluded. To reduce the possibility of duplication, each ADR was 
individually compared based on the patient’s age, sex, and residence; 
location of the participating pharmacy; date of onset of the reaction; 
and related drugs.  
The patient population was classified into three age groups: children 
(less than 18 years), adult (19–63 years), and elderly (more than 64 
years) groups. Reports without age were excluded. Patient records were 
anonymized and de-identified prior to analysis. The Institutional 
Review Board of Seoul National University approved this study (IRB 





Causality assessment  
 
The causality of a drug for ADR was assessed using the World 
Health Organization-Uppsala Monitoring Centre (WHO-UMC) criteria, 
which was composed of six categories: certain, probable, possible, 
unlikely, conditional, and unassessable [15]. Causality was 
independently assessed by two trained pharmacists. When the 
pharmacists disagreed on causality, they discussed the difference and 
achieved consensus in all cases. The inter-rater reliability in initial 
assessment was calculated and Cohen’s κ score greater than 0.81 was 
considered “very good agreement” [16]. ADRs classified as “less than 
possible” in the causality assessment were excluded from subsequent 
analysis. 
 
Analysis of clinical manifestations and causative 
drugs 
 
Clinical manifestations were classified using the WHO-adverse 
reaction terminology (ART) system [17]. The system-organ classes 
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(SOC) and the preferred terms (PT) of the WHO-ART system were 
used as a main- and sub-category, respectively. Symptoms matched 
with the same PT were treated as the same event. Two or more PTs 
reported in one patient and two or more medications involved in one 
event were counted as different ADRs. The causative drugs were 
classified using the Anatomical Therapeutic Chemical (ATC) 
classification system [18]. 
The frequency of clinical manifestations and causative drugs was 
compared according to age group. Unlabeled ADRs were identified by 
assessing whether reported ADRs were included in the label of each 
causative drug. The relationship between serious ADRs and causative 
drugs was evaluated by comparing the count of specific ADRs 
according to specific drugs. 
 
Analysis of serious events and nonprescription 
drugs  
 
Serious ADRs were defined as cases that were fatal, caused 
hospitalization or persistent disability, or were life-threatening 
according to WHO criteria [19]. The patterns of ADRs caused by 
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nonprescription drugs were also analyzed by comparing the number of 




Descriptive statistics were used to summarize the demographic and 
clinical characteristics of study participants. Means and standard 
deviations were used for continuous variables, whereas frequencies and 
percentages were used for categorical variables. The categorical 
characteristics of three age groups including children, adults, and 
elderly were compared. Chi-squared test or Fisher’s exact test was 
applied to compare categorical variables between groups. The 
significance level was set at p < 0.01. For post hoc analysis, chi-
squared test or Fisher’s exact test with Bonferroni correction was 
employed and the significance level was set at p < 0.003. Data analysis 











From January 2013 to June 2014, 42,018 ADRs from 9,919 patients 
were reported. A total of 920 community pharmacies participated. The 
proportion of participating community pharmacies located in 
metropolitan versus rural areas was 59.4% versus 40.6%. Forty-six 
patients (88 ADRs) were excluded because of a lack of information 
about age. Causality assessment using WHO-UMC criteria for 41,930 
ADRs in 9,873 patients classified 1.4% as certain, 5.4% as probable, 
68.1% as possible, 24.7% as unlikely, 0.2% as conditional, and 0.2% as 
unassessable. The κ score was 0.83 showing "very good agreement" 
between the initial assessments of causality. After exclusion of the 
10,532 ADRs (25.1%) having a less than possible degree of causality, 
31,398 ADRs (74.9%) in 9,705 patients were analyzed. The mean 
number of events per patient was 1.4 and the mean number of causative 







Fig. 1. The selection process for adverse drug reaction reports. 
ADR, adverse drug reaction; RPVC-KPA, Regional Pharmacovigilance 
Center-Korean Pharmaceutical Association; WHO-UMC, World Health 





Demographic characteristics  
 
The median age of the 9,705 patients was 58.0 years, ranging 3 
months to 98 years (Table 1). The adult group comprised the largest 
portion of patients (64.0%), followed by the elderly group (32.5%) and 
children (3.5%). Females comprised 66.9% of all patients, with similar 
distributions in the adult and elderly subgroups. In contrast, female 
children comprised less than half of the pediatric group, which 






Table 1. Patient demographics 
Characteristics Value 
Number of patients 9,705 
Female (%) 66.9 
Age, median (range, years) 58.0 (0.3–98.0) 
Age, n (%)  
Children 341 (3.5) 
<2 years 61 (0.6) 
2–11 years 165 (1.7) 
12–18 years 115 (1.2) 
Adults (19–64 years) 6,209 (64.0) 
Elderly 3,155 (32.5) 
65–74 years 2,076 (21.4) 
75–84 years 965 (9.9) 
≥85 years 114 (1.2) 
Reported events per patient (mean) 1.4 
Reported drugs per event (mean) 2.3 





Clinical manifestations of adverse drug reactions 
 
The clinical manifestations most frequently associated with ADRs 
were gastro-intestinal (GI) system disorders (4,623 events, 34.4%) 
followed by nervous system disorders (1,932 events, 14.4%) and 
psychiatric disorders (1,620 events, 12.1%). The most common 
symptoms were dizziness (1,142 events, 8.5%), dyspepsia (1,139 
events, 8.5%), and somnolence (847 events, 6.3%). 
A comparison of clinical manifestations according to age revealed 
that GI system disorders and diarrhea were most common in children, 
but dry mouth was least frequent in this group (p < 0.001) (Table 2). 
The leading drugs causing diarrhea in children were antibacterial agents. 
The elderly group showed a significantly higher frequency of ADRs 
involved in nervous and urinary system disorders (p < 0.001). 
Dizziness was reported more frequently in the elderly than in any other 
age group (p < 0.001). The main drugs causing dizziness in elderly 
were analgesics and antiepileptics. Psychiatric disorders (including 
their subcategory somnolence) and skin disorders (including their 
subgroup rash and urticarial) were more frequent in children and adults 
(p < 0.001) (Table 2). 
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Table 2. Clinical manifestation of adverse drug reactions according to 




















































Dry mouth 570 
(4.2) 
































































































































































Face edema 340 
(2.5) 

















































dNumber of events and percentage of individual events within each group. 
eChi-squared test of the three groups. 






The most prevalent causative drugs were alimentary tract and 
metabolism drugs (6,984 ADRs, 22.2%), followed by musculoskeletal 
system drugs (5,436 ADRs, 17.3%) and nervous system drugs (5,210 
ADRs, 16.6%). According to the subclassification, drugs for acid-
related disorders (3,588 ADRs, 11.4%), anti-inflammatory products 
(3,305 ADRs, 10.5%), analgesics (2,262 ADRs, 7.2%), and 
antibacterials (2,240 ADRs, 7.1%) were frequently associated with 
ADRs. 
Drugs acting on the respiratory system and anti-infective drugs were 
more frequently involved in ADRs in the pediatric population than in 
other groups (p < 0.001). Drugs for the nervous system, cardiovascular 
system, genitourinary system and sex hormones, and blood and blood-
forming organs were reported more frequently as causative drugs for 
ADRs in the elderly (p < 0.001) (Table 3). Unlabeled ADRs were not 
identified. A comparison of causative drugs according to sex revealed 
that urological agents were more prevalently involved in ADRs in 
males (p < 0.001) (Fig. 2). 
Drugs for acid related disorders and anti-inflammatory products were 
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the most common causative drugs for nervous system adverse reactions.   
However, ADRs involving nervous system comprised highest 
proportions of ADRs which were reported to be related with 
antithrombotic agents and beta-blocking agents. Also, psychiatric 
disorders comprised largest proportion of ADRs associated with 
antiobesity and nasal preparations while antihistamines and drugs for 
acid related disorders were the most frequent suspect drugs of 
psychiatric disorders. Among the skin disorders, anti-inflammatory 
products and drugs for acid related disorders were the most common 
offending drugs. However the drugs with the highest proportion in skin 
disorders, were topical products for joint and muscle pain and 




Table 3. Causative drugs for adverse drug reactions according to the 
second level of anatomical therapeutic chemical classification systemd 
Causative drugs Total 
(%) 





































































Muscle relaxants 1,057 2 (0.2) 721 334 <0.001 a<b,c 
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(3.4) (3.6) (3.2) 
Others 1,074 
(3.4) 





Nervous systemj 5,210 
(16.6) 





































































Drugs for OA 769 80 (7.9) 433 256 <0.001 a>b,c 
２２ 
 





51 (5.0) 347 
(1.7) 
93 (0.9) <0.001 a>b>c 
others 79 
(0.3) 







































































GU system and 874 2 (0.2) 495 377 <0.001 a<b<c 
２３ 
 
sex hormonesn (2.8) (2.5) (3.6) 
Urologicals 629 
(2.0) 







1 (0.1) 217 
(1.1) 











Corticosteroids  733 
(2.3) 







1 (0.1) 75 (0.4) 39 (0.4)   




















2 (0.2) 120 
(0.6) 
49 (0.5)   
Antineoplasticsq 546 
(1.7) 







14 (1.4) 185 
(0.9) 
53 (0.5) <0.001 c<a,b 
２４ 
 
GI, gastro-intestinal; OA, obstructive airway; GU, genito-urinary. 
dNumber of adverse drug reactions (ADRs) and percentage of individual 
ADRs within each group. 
eChi-squared test among the three groups. 
fChi-squared test between the adult and elderly groups. 
gBonferroni correction (p < 0.003) with chi-squared test or Fisher’s exact test.  
hRanitidine,  pantoprazole, levosulpiride, trimbutine, metformin, and 
glimepiride, etc. 
iIbuprofen, loxoprofen, chlorphenesin, and orphenadrine, etc. 
jAcetaminophen, combination of acetaminophen and tramadol, valproate, 
gabapentin, alprazolam, risperidone, donepezil, and duloxetine, etc. 
kOlopatadine, levocetirizine, combination of chlorpheniramine and 
dihydrocodeine, combination of acetaminophen and ephedrine, montelukast, 
theophylline, combination of pseudoephedrine and triprolidine, and 
pseudoephedrine, etc. 
lAtorvastatin, pravastatin, combination of valsartan and amlodipine, 
combination of telmisartan and amlodipine, amlodipine, and diltiazem, etc. 
mCombination of amoxicillin and clavulanate, cefaclor, and ciprofloxacin, etc. 
Sensory organss 250 
(0.8) 







3 (0.3) 61 (0.3) 21 (0.2)   
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nPentosan polysulfate, terazosin, and tolterodine, etc. 
oDexamethasone, triamcinolone, and methylprednisolone, etc. 
pAspirin, clopidogrel, and warfarin, etc. 
qCyclosporine, mycophenolate, and capecitabine, etc. 
rTerbinafine, clobetasol propionate, and benzoyl Peroxide, etc. 








Fig. 2. Frequency of adverse drug reactions and causative drugs 
according to sex. GI, gastrointestinal; RAS, renin-angiotensin system; 







Figure 3. The number of specific adverse drug reaction case and the 







In total, 66 serious events were identified in 52 patients who 
experienced a life-threatening event (15 patients), hospitalization (36 
patients), or persistent disability (1 patient). The life-threatening events 
included symptoms associated with anaphylactic reactions, dyspnea, 
and circulatory failure. The persistent disability involved blindness and 
ocular hemorrhage associated with everolimus, an antineoplastic agent. 
The proportion of serious events in adults and elderly groups was 0.58% 
and 0.51%, respectively. There were no serious event reports for the 
pediatric population. Among serious events, the most common 
symptoms were anaphylactic reaction (13 events, 19.7%) (Table 4). 
Cephalosporins and non-steroidal anti-inflammatory drugs (NSAIDs) 
were most frequently associated with this symptom. Non-steroidal anti-
inflammatory drugs (NSAIDs) (18 ADRs, 19.8%), analgesics (17 
ADRs, 18.7%), and antibacterials (13 ADRs, 14.3%) were the main 









Clinical manifestation (n) a 
General disorders 16 (24.2) Anaphylactic reaction (13), edema 
(2), asthenia (1) 
Gastro-intestinal 
system disorders  
15 (22.7) Vomiting (8), abdominal pain (3), 
gastro-intestinal hemorrhage (2), 
dyspepsia (1), tongue disorder (1) 
Nervous system 
disorders 
13 (19.7) Dizziness (9), headache (1), vocal 




6 (9.1) Circulatory failure (2), ocular 
hemorrhage (1), palpitation (1), 




3 (4.5) Dyspnea (3) 
Urinary system 
disorders 
3 (4.5) Dysuria (3) 
３０ 
 
Liver and biliary 
system disorders 
3 (4.5) Hepatic enzyme increased 
Skin disorders 2 (3.0) Bullous eruption (1), rash (1) 
Vision disorders 2 (3.0) Blindness (1), vision abnormal (1) 
Reproductive 
disorders 
2 (3.0) Uterine hemorrhage (1), 
intermenstrual bleeding (1) 
Metabolic 
disorders 
1 (1.5) Hypoglycemia (1) 










Clinical manifestation (n)a 
Anti-inflammatory 
productsb 
18 (19.8) AR (8), edema (2), vomiting (2), 
dizziness (2), CF, uterine 
hemorrhage, bullous eruption, 
vision abnormal 
Analgesicsc 17 (18.7) AR (3), vomiting (5), AP, 
dizziness (5), headache, HE 
increased, dyspnea  
Antibacterialsd 13 (14.3) AR (9), AP, GI hemorrhage (2), 
dyspepsia 
Urologicals 5 (5.5) asthenia, dizziness, hypotension 
postural, dysuria (2) 
Psychoanaleptics 4 (4.4) vomiting, AP, dysuria, palpitation 
Drugs used in 
diabetes 
4 (4.4) CF, dyspnea, hypoglycemia (2) 
Antithrombotic agents 4 (4.4) GI hemorrhage (2), CF, dyspnea 
Antiepileptics 2 (2.2) vomiting, dizziness 
３２ 
 
Digestives 2 (2.2) tongue disorder, dyskinesia 
Drugs for acid related 
disorders 
2 (2.2) GI hemorrhage, hypertension  
Drugs for functional 
GI disorders 
2 (2.2) vocal cord paralysis, dystonia 
Sex hormones  2 (2.2) dizziness, intermenstrual bleeding  
Cough and cold 
preparations 
2 (2.2) AR, rash 
Drugs for OA disease 2 (2.2) AR, AP 
Peripheral 
vasodilators 
2 (2.2) vomiting, dizziness  
Antineoplastic agents 2 (2.2) blindness, ocular hemorrhage 
Antivirals  1 (1.1) vomiting 
Antimycotics  1 (1.1) HE increased 
Nasal preparations 1 (1.1) dysuria  
Cardiac therapy 1 (1.1) CF  
Lipid modifying  
agents 
1 (1.1) CF 
Agents acting on the 
RAS 
1 (1.1) vomiting 
３３ 
 
Immunosuppressants 1 (1.1) HE increased 
Corticosteroids  1 (1.1) HE increased 
ADRs, adverse drug reactions; GI, gastrointestinal; OA, obstructive airway 
diseases; RAS, renin-angiotensin system; AR, anaphylactic reaction; AP, 
abdominal pain; HE, hepatic enzyme; CF, circulatory failure. 
aNumbers in parentheses indicate the number of adverse drug reactions. 
bDexibuprofen, loxoprofen, and celecoxib, etc. 
cCombination of acetaminophen and tramadol, buprenorphine, and 
sumatriptan, etc. 







Nonprescription drugs were implicated in 394 patients and 680 
ADRs. The adult group comprised the largest portion of patients 
(76.4%), followed by the elderly group (18.8%) and children (4.8%). 
Skin disorders (181 events, 29.6%) including rash and pruritus were the 
most frequently reported manifestations, followed by GI system 
disorders (155 events, 25.3%) such as dyspepsia and nausea. Among a 
total of 186 causative drugs, NSAIDs (110 ADRs, 16.2%) and topical 
products for joint and muscular pain (56 ADRs, 8.2%) were most 
common. A combination drug containing acetaminophen and 
chlorzoxazone (40 ADRs, 5.8%) was the most prevalent individual 
drug, followed by naproxen (37 ADRs, 5.4%) and ibuprofen (29 ADRs, 
4.2%) (Table 6). A comparison of ADRs by nonprescription drugs 
according to age in 394 patients revealed that NSAIDs and GI system 
disorders were more frequently involved in children than in other 
groups (p < 0.001). NSAIDs and GI system disorders respectively 















40 (5.8) dizziness (10), pruritus (3), urticaria 
(3), dyspepsia (3), vomiting (3), 
nausea (3), rash (2) 
Naproxen 37 (5.4) dyspepsia (6), edema (4), pruritus (4), 
rash (4), abdominal pain (2) 
Ibuprofen 29 (4.2) dyspepsia (4), vomiting (3), 
abdominal pain (3), urticaria (3), 
dizziness (2) 
Ketoprofen patch 17 (2.5) rash (6), pruritus (4), skin exfoliation 
(2) 




15 (2.2) edema periorbital (4), pruritus (3), 





13 (1.9) rash (4), pruritus (2), skin exfoliation 
(2), dermatitis (2) 
Clonixin 9 (1.3) urticaria (3) 
Alimentary tract  
Antacid 
combinationsc  




18 (2.6) insomnia (4), dizziness (2), sweating 
increase (2), somnolence (2) 
Cetirizine 11 (1.6) headache (2), somnolence (2) 
Flurbiprofen 8.75 
mg 




25 (3.6) edema (3), nausea (3), rash (3), 
urticaria (2), vomiting (2), dyspnea 
(2), drug dependence (2) 
Gingko leaf ext. 10 (1.4) pruritus (2), dyspepsia (2) 
Nicotine patch 9 (1.3) dermatitis (3), pruritus (2) 
Diphenhydramine 7 (1.0) abdominal pain (2) 





18 (2.6) abdominal pain (4), rash (2), nausea 
(2), acne (2) 
Desogestrel/ 
ethinyl Estradiol 
14 (2.0) menstrual disorder (4), nausea (2), 
weight increase (2) 
Gestodene/ethinyl 
Estradiol 




8 (1.2) rash (3), pruritus (2) 
ADRs, adverse drug reactions; GU, genito-urinary. 
a680 adverse drug reactions from 394 patients. 
bClinical manifestations reported for more than one adverse drug reaction and 
the number of adverse drug reactions. 
cCombinations of aluminum magnesium silicate/ranitidine/magnesium 













To the best of our knowledge, this is the first large-scale study of CP-
reported ADRs in outpatients in Korea. Reports of clinical 
manifestations affecting the GI system, nervous system, and psychiatric 
disorders were prevalent. The most frequent causative drugs were those 
used to treat acid-related disorders, anti-inflammatory products, 
analgesics, and antibacterials. ADR patterns differed by age group. Our 
findings suggest the need to establish 
pharmacovigilance strategies adapted to outpatient characteristics and 
age group. 
In this study, females comprised around two-thirds (66.9%) of the 
study cohort who had experienced ADRs, which could be explained by 
the epidemiological population distribution (female, 58.3%) among the 
average daily number of outpatients [20]. A multinational study 
reported that the ADR reporting rate of antidepressants was not 
significantly different between men and women when considering drug 
consumption [21]. However, other studies have suggested a 
preponderance of ADRs in female patients [13,22,23]. The higher 
adverse event rate in females has been found to result from differences 
in pharmacokinetic factors [22], hormonal factors [24], drug 
prescription rate [23], medical care utilization [20,25], propensity of 
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symptom reporting [25], and a historical lack of drug research in this 
population [26]. In the present study, women also experienced more 
than twice the number of anaphylactic reactions compared to men. 
Ribeiro-Vaz et al. also showed that females are more likely to 
experience anaphylaxis [27]. 
Comparison of the ADR reports by CPs with the entire set of ADR 
reports to KIDS during the same period showed that the prevalent ADR 
symptoms were GI and nervous system disorders and the most frequent 
causative drugs were anti-inflammatory products, analgesics, and 
antibacterials in both reports [10]. However, the proportion of serious 
events (0.54%) in reports by CPs was much lower than that in the entire 
ADR dataset (11.2%) [10], which can be explained mainly by the 
relatively less severe medical state of outpatients and by the limited 
experience of CPs in ADR reporting. The non-seriousness that prevails 
in early periods of pharmacovigilance by a new expert group may be 
one of the reasons for the low proportion of serious events in this study 
[28].  
The clinical manifestations and causative drugs showed specific 
trends according to age. In the pediatric group, GI system disorders, 
especially diarrhea, and antibacterial agents were most frequent. These 
results are consistent with previous reports. Two systematic reviews 
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and a prospective cohort study showed that antibacterial agents and GI 
disorders were the leading causes and symptoms, respectively, of 
ADRs in pediatric outpatients [14,29,30]. In this study, antibacterial 
agents comprised 46.1% of the drugs causing diarrhea in children. 
Infants aged less than 24 months and patients taking broad-spectrum 
penicillins or cephalosporins accounted for 37.0% and 81.9% of the 
children who experienced antibacterial-associated diarrhea. These 
results are consistent with the risk associated with reduced fecal flora in 
infants and broad-spectrum penicillins and cephalosporins in pediatric 
diarrhea [31,32]. 
Dizziness was the most common symptom in the elderly, consistent 
with reports of a 30% prevalence in older populations [33]. Maarsingh 
et al. showed that medications were the second leading cause of 
dizziness following comorbidities such as cardiovascular and peripheral 
vestibular disease in the elderly [34]. In this study, the main drugs 
associated with dizziness were those used to treat the nervous system 
(29.5%), such as combination drugs containing acetaminophen and 
tramadol (9.3%), gabapentin (3.9%), and pregabalin (3.8%). 
Considering the risk of secondary injury resulting from dizziness in the 
elderly, use of these drugs should be carefully monitored and evaluated. 
Cephalosporin antibiotics and NSAIDs were mainly associated with 
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anaphylactic reactions, which was the major clinical manifestation in 
serious events. A review of a decade of spontaneous ADR reports 
showed similar results; antibiotics and the combination of NSAIDs and 
acetaminophen were primarily responsible for the incidence of 
anaphylaxis [27]. 
For nonprescription drugs, skin and GI system disorders were most 
prevalent, and were chiefly caused by NSAIDs such as naproxen and 
ibuprofen. A prospective multi-center study also reported that the most 
frequent nonprescription drugs causing ADR-related hospital 
admissions were NSAIDs including aspirin, diclofenac, and ibuprofen; 
the leading symptoms were GI disorders [35].  
This study has several limitations. First, we relied on spontaneous 
reporting, which is subject to under-reporting and lack of information 
[36,37]. All data were retrospective and we were unable to confirm 
accuracy or replace missing data. However, spontaneous reporting by 
CPs has the advantages of providing the direct outpatient complaints 
[38]. Second, although these pharmacovigilance systems are intended 
to detect signals, unlabeled ADRs were not identified; therefore, we 
could not suggest any potential signals. Third, we could not account for 
the size of the at-risk population because of a lack of information on 
substantial drug usage (the number of prescriptions for each causative 
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drug at each participating pharmacy) in outpatients. Because commonly 
prescribed drugs are more likely to be the offenders in ADR events [39], 
considering the prevalence of drug usage might aid in the interpretation 













In summary, among the outpatient ADRs spontaneously reported by 
CPs, those involving the GI system, nervous system, and psychiatric 
disorders were prevalent. Anti-inflammatory products, analgesics, and 
antibacterials were the leading causes of ADRs, including serious 
events. The patterns of outpatient ADRs reported by CPs also differed 
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Appendix 1.  
 
The Clinical Characteristics of Adverse Drug Reactions Reported 
from the Community Pharmacy 
 
Objective: To evaluate the clinical manifestations and causative drugs of the 
outpatient adverse drug reactions (ADRs) reported by community pharmacy. 
Methods: From April 2013 to September 2013, all outpatient ADRs reported 
by community pharmacy to Regional Pharmacovigilance Center of Korean 
Pharmaceutical Association were included. The causality of ADRs was 
assessed by the criteria of WHO-Uppsala Monitoring Centre. The clinical 
features and the offending drugs were analyzed using the WHO-Adverse 
Reaction Terminology and the classification of American Hospital Formulary 
Service Drug Information, respectively. Results: 2,826 (97.0%) of the total 
2,912 ADRs had causal relationship. The 1,923 patients with mean age of 55.1 
years and female fraction of 66.5% were included in the ADRs. 
Gastrointestinal (33.6%), nervous system (14.9%), and skin (13.5%) 
symptoms were common in ADRs. Analgesic drugs (19.7%), gastrointestinal 
drugs (17.7%), and central nervous system drugs (11.0%) were prevalent 
offending drugs. The leading causative generic drug was the complex of 
acetaminophen and tramadol. Among 203 ADRs by the nonprescription drugs, 
the most common clinical features were skin (37.4%) and gastrointestinal 
５６ 
 
(23.6%) symptoms and the most prevalent offending drugs were analgesic 
drugs (40.0%) and mucocutaneous system drugs (16.3%). The combination of 
acetaminophen and chlorzoxazone was the leading causative generic in 
nonprescription drugs. Conclusion: In this study, gastrointestinal symptom 
was the most common manifestation and analgesic drug was the most 




연구대상 및 자료수집 
2013년 4월부터 9월까지 6개월간, 전국 지역약국과 
외래환자로부터 대한약사회 지역의약품안전관리센터에 보고된 ADR 
사례를 대상으로 하였다. 각 ADR 보고로부터 환자의 이름, 성별, 
생년월일, ADR 증상, 의심약물의 투여 시작일 및 종료일, 
증상발현일, 증상에 대한 조치, 재 투여 시 증상발현 여부, 의심약물 
및 병용약물, 처방의약품 여부 (처방조제, 약국일반의약품, 
안전상비의약품, 기타 중 택일), 보고 약국명 및 지부소속에 관한 
자료를 수집하였다.  
한 보고사례에서 두 가지 이상의 증상이 발생한 경우에 서로 
다른 보고 건수로 간주하였으며, 한 가지 증상이 두 가지 이상의 
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약물에 의해 발생한 경우에 해당 약물 모두를 원인약물로 
간주하였다. 또한, 환자의 이름, 성별, 생년월일, 보고약국의 
지부소속, 의심약물 및 ADR증상이 모두 일치하는 경우, 한 환자가 
동일한 약물에 대해 같은 증상의 ADR을 2회 이상 보고한 것으로 
판단하여 동일 보고사례로 간주하였다.  
ADR 사례에서 환자의 성별이나 나이 정보가 없는 경우, 해당 
사례를 성별이나 나이에 따른 분석에서는 제외하였고, 이외 
기술통계학적 분석에는 포함하였다. 
 
약물유해반응의 인과성 평가 
약물과 ADR 간의 인과성평가는 World Health Organization-
Uppsala Monitoring Centre (WHO-UMC) 기준을 근거로 하였으며, 
확실함 (certain), 가능성 높음(probable), 가능성 있음(possible), 




기준에서 가능성 있음(possible) 이상으로 평가된 경우에 대해서만 
유의한 ADR로 간주하고 분석에 포함하였다. 
 
약물유해반응의 증상 분류 
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ADR 증상의 분류에는 32개의 기관분류(system organ classes)와 
180개의 상급용어(high level terms) 및 2,085개의 우선용어(preferred 
terms), 3,445개의 포함용어(included terms)로 이루어져 있는 World 
Health Organization Adverse Reaction Terminology(WHOART) 코드 
체계를 사용하였다.
17,18)
 먼저 지역약국이나 외래환자가 보고한 ADR 
증상과 일치하는 포함용어나 우선용어를 검색하였고, 이에 해당되는 
기관분류를 선택하였다. 단, 본 연구에서는 Common Terminology 
Criteria for Adverse Events (CTCAE) v4.0 분류를 참고로,
19)
 
WHOART의 기관분류 1코드가 동일한 경우 한 분류로 통합하고, 
근골격계 이상과 콜라겐 이상을 근골격계 및 콜라겐 이상으로 
통합하여, 32개로 이루어진 기관분류를 19개의 ADR 증상 분류로 
표시하였다. 19개의 증상 분류는 피부, 근골격계, 신경계, 안과 및 
이비인후과적, 정신과적, 위장관계, 간담도계, 대사 및 영양관련, 
내분비계, 심혈관계, 호흡기계, 혈액계, 비뇨기계, 생식기계, 
태아관련, 신생아 및 유아관련, 종양관련, 전신성, 기타 증상으로 
나누었다(Index 1).  
 
원인약물의 약효별 분류 
원인약물의 약효별 분류에는 American Hospital Formulary Service 
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Drug Information 기준을 사용하였다.
20)
 단, 본 연구에서는 
Anatomical Therapeutic Chemical (ATC) Classification System 
분류를 참고로 하여,
21)
 평활근육 이완제와 기타약물 항목에서 
비뇨생식기계 약물을 분리하였다. 또한, 기존 연구들에서 진통제를 
별도로 분류하여 ADR 보고빈도를 나타낸 점을 고려하여,
7-12)
 
중추신경계 약물항목에서 진통제를 분리하여 표시하였다. 이에 따라 
원인약물들은 진통제, 항히스타민제, 항감염제, 항암제, 
자율신경계약 및 근이완제, 혈액생성 및 응고관련 약물, 심혈관계 
약물, 중추신경계 약물, 진단관련 약물, 전해질 및 열량 조절제, 
안과 및 이비인후과 약물, 위장관계 약물, 비뇨생식기계 약물, 
호르몬제, 호흡기계 약물, 피부 및 점막 약물, 비타민 및 무기질, 
기타 약물 등 18개 약효군으로 분류하였다(Index 2). 
 
일반의약품 및 안전상비약품의 분석 
처방전 없이 구입하여 복용한 일반의약품과 안전상비약품의 
경우를 처방의약품과 구분하여 해당 약물들의 ADR 증상과 약효별 





기술통계분석을 사용하여 연속형 변수는 평균과 표준편차로 




약물유해반응의 보고양상 분석 
총 1,967명 환자에서 2,912건의 ADR 의심사례가 보고되었다. ADR 
보고 사례수는 4월에 153예에서 5월 263예, 6월 265예, 7월 337예, 
8월 404예, 9월에는 545예로 꾸준히 증가하였다. 지역별 사례수는 
서울지역 492예, 부산지역 481예, 경기지역 330예, 인천지역에서 
143예가 보고되었다. ADR 보고에 참여한 약국은 총 316개 
약국이었으며, 지역별로는 경기지역 74개, 서울지역 54개, 부산지역 
44개, 인천지역에서 31개 약국이 참여하였다. 
 
약물유해반응의 인과성 평가 
전체 2,912건의 보고건수에 대해 약물과 유해반응간의 인과성을 
WHO-UMC 기준으로 평가하였을 때, 확실함 120건(4.1%), 가능성 
높음 524건(18%), 가능성 있음 2,182건(74.9%), 가능성 적음 
72건(2.5%), 평가곤란 14건(0.5%))으로 가능성 있음이 가장 많았다. 
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가능성 있음(possible) 이상으로 평가된 ADR만을 약물과 인과관계가 
있다고 판단하고, 해당 환자 1,923명, 보고건수 2,826건(97.0%)에 
대해 분석을 시행하였다. 
 
환자 특징 
유의한 인과관계를 보인 환자 1,923명중 연령이 보고된 환자는 
1,828명이었고, 평균연령±표준편차는 55.1±17.0세였다. 12세 미만의 
소아는 40명(2.2%), 12세이상 19세미만의 청소년층은 24명(1.3%), 
19세이상 65세미만의 성인은 1,188명(65.0%), 65세 이상의 노인은 
576명(31.5%)으로 성인이 가장 많았다. 성별이 보고된 환자는 
1,812명이었으며, 이중 남성이 607명(33.5%), 여성이 
1,205명(66.5%)이었다. 연령대별 여성의 비율은 소아에서 52.8%, 
청소년층에서 50.0%, 성인에서 67.9%, 노인에서 64.2%로, 청소년층을 
제외한 전체 연령대에서 여성의 비율이 남성보다 높았다. 환자 
1인당 ADR 발생 건수는 평균 1.5건이었고, ADR 발생 건수당 관련 
약물 수는 평균 2.2개로 나타났다. 
 
약물유해반응 증상의 분석 
ADR 증상의 분류별 발생빈도는 위장관계 증상이 
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950건(33.6%)으로 가장 많이 나타났으며, 다음으로 신경계 증상이 
420건(14.9%), 피부 증상이 382건(13.5%), 전신성 증상이 
380건(13.4%)으로 많았다(Table 1). 단일 증상으로 가장 빈도가 
높았던 ADR 증상은 현기증으로 250건(8.8%)이었고, 복부불편감이 
164건(5.8%), 오심이 154건(5.4%), 졸림이 151건(5.3%)으로 빈도가 
높게 나타났다(Table 1). 
 
원인약물의 분석 
원인약물을 약효별로 분류하였을 때, 진통제가 1,204건(19.7%)으로 
가장 많았으며, 다음으로 위장관계 약물이 1,103건(17.7%), 
중추신경계 약물이 683건(11.0%), 심혈관계 약물이 594건(9.6%)으로 
많았다(Table 2). 성분별 주요 약물로는 acetaminophen/tramadol 
복합제 (383건), ranitidine (156건), aceclofenac (145건), mosapride 
(136건), streptokinase/streptodornase 복합제 (130건), eperison 
(114건), rebamipide (112건), loxoprofen (111건), acetaminophen 
(108건), Artemisia asiatica herb (88건), cefaclor (83건), 
amoxicillin/clavulanate 복합제 (82건), gabapentin (80건)이 높은 




일반의약품 및 안전상비약품의 약물유해반응 분석 
일반판매의약품 및 안전상비약품에서는 114명의 환자에서 
203건의 ADR이 보고되었으며 해당 약품은 105개 품목이었다. ADR 
증상은 피부 증상이 76건(37.4%)으로 가장 많이 나타났으며 
다음으로 위장관계 증상이 48건(23.6%), 신경계 증상이 24건(11.8%), 
전신성 증상이 22건(10.8%)으로 많았다. 가장 빈도가 높았던 증상은 
가려움증과 발진으로 각각 20건(9.9%)이었고, 다음으로 두드러기가 
15건(7.4%), 현기증과 구토가 각각 11건(5.4%)으로 빈도가 높게 
나타났다(Table 3). 원인약물로는 진통제가 86건(40.0%)으로 가장 
많았으며, 다음으로 피부점막계 약물이 35건(16.3%), 비타민 및 
무기질계 약물이 20건(9.3%)으로 많았다. 약품으로는 
acetaminophen/chlorzoxazone 복합제와 ketoprofen 플라스타제제가 




Table 1. Frequency of clinical manifestations in adverse drug reactions 
Classification No. of 
reports 
(%) 





Abdominal discomfort (164), 
nausea (154), vomiting (129), 
diarrhea (101), mouth dry (91) 
Nervous system disorders  420 
(14.9) 
Dizziness (250), headache (76), 
tremor (29), sensory disturbance 
(25), limpness body (9) 




Pruritus (114), Skin eruption (104), 
urticaria (50), diaphoresis (16), 
alopecia (13) 
General disorders  380 
(13.4) 
Facial or generalized  edema 
(122), asthenia (67), fatigue (35), 
fever (23), facial flush (21) 
Psychiatric disorders  310 
(11.0) 
Somnolence (151), insomnia (95), 
anorexia (19), anxiety (7) 
Vision/ Hearing/ 
vestibular disorders  
76  (2.7) Visual disturbance (28), taste 
alteration (18), red eye (9), eye 
pain (8) 
Cardiovascular disorders  63  (2.2) Palpitation (37), hypotension (10),   
hypertension (7)  
Respiratory system 
disorders  
58  (2.1) Coughing (17), dyspnea (15), 
epistaxis (4), sore throat (4) 
Urinary system disorders  50  (1.8) Urine discoloration (18), dysuria 
(16), urinary retention (5) 
Metabolic and nutritional 
disorders  





collagen disorders  
41  (1.5) Myalgia (25), arthralgia (6) 
Reproductive disorders  27  (1.0) Lactation nonpuerperal (9), breast 
pain (6),  
Blood cell/ clotting 
disorders  
11  (0.4) Bruise (10), bleeding time 
increased (1) 
Liver and biliary system 
disorders  
7  (0.2) Hepatic enzymes increased (6) 
Endocrine disorders  3  (0.1) Gynecomastia (3) 
Neoplasms 2  (0.1) Breast cyst(1), breast fibrosis(1) 
Miscellaneous 3  (0.1) Application site burning (2), 




Table 2. Frequency of drugs to cause the adverse drug reactions 
 
Classification No. of 
reports (%) 
Main drugs (n) 
Analgesics  1204 (19.7) Acetaminophen+tramadol (383), 
acetaminophen (108), tramadol (15), 
aceclofenac (145), loxoprofen (111), 
meloxicam (64), talniflumate (56), 
dexibuprofen(53), ibuprofen (51), 
Gastrointestinal 
drugs 
1103 (17.7) Ranitidine (156), mosapride (136), 
rebamipide (112), Artemisia asiatica herb 




683 (11.0) Gabapentin (80), pregabalin (77), 
alprazolam (47), hydroxyzine (44), 
diazepam (26), clonazepam (23) 
Cardiovascular drugs 594  (9.6) Atorvastatin (58), amlodipine+telmisartan 
(19), amlodipine (46), telmisartan(8), 
propranolol (30), hydrochlorthiazide + 
losartan (13), hydrochlorthiazide (23), 
losartan (14) 
Anti-infective agents 571  (9.2) Cefaclor (83), amoxicillin+clavulanate 
(82), clarithromycin (36), levofloxacin 
(28), ofloxacin (26) 
Respiratory agents 361  (5.8) Guaifenesin+chlorpheniramine+dihydroc
odeine+methylephedrine (43), erdosteine 
(29), acetylcysteine (28), montelukast 
(26), pseudoephedrine (26) 
Hormones and 
synthetic substitutes 
356  (5.7) Prednisolone (74), methylprednisolone 
(66), metformin +sitagliptine (8), 
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metformin (47), sitagliptine (7), 
glimepiride (28) 
Antihistamine drugs 276  (4.4) Levocetrizine (51), azelastine (49), 
bepotastine (37), chlorpheniramine (25), 
fexofenadine (24) 
Autonomic drugs & 
skeletal muscle 
relaxants 
203  (3.3) Eperisone (114), chlorphenesin (24), 




118  (1.9) Aspirin 100mg (37), clopidogrel (25), 
ferrous sulfate (15), cilostazol (12), 
warfarin (10) 
Genitourinary agents 118  (1.9) Tamsulosin (23), terazosin (15), 
solifenacin (14), alfuzosin (12), 
propiverine (12)  
Antineoplastic 
agents 
95  (1.5) Capecitabine (29), methotrexate (19), 
sunitinib (10), gefitinib (8), erlotinib (6) 
Vitamins 95  (1.5) Cholecalciferol+CaCO3 (13), 
Cholecalciferol+Ca citrate (12), 
isotretinoin (15), folic acid (8) 
Skin and mucous 
membrane agents 
65  (1.0) ketoprofen (14), Benzoyl peroxide (6), 
terbinafine (5),  
Eye, ear, nose and 
throat preparations 
61  (1.0) Benzydamine (9), hyaluronate (9), timolol 
(3),  timolol+dorzoamide(3), 
timolol+travoprost (2) 
Miscellaneous 292  (4.7) streptokinase+streptodornase (130), 
risedronate (18),  tacrolimus (15), 




Table 3. Frequency of clinical manifestations of adverse drug reactions on 
non-prescription drugs 
Classification No. of 
reports 
(%) 
Main manifestations (n) 
Skin and appendages 
disorders  
76 (37.4) Pruritus (20), Skin eruption (20), 
urticaria (15),  
Gastro-intestinal system 
disorders  
48 (23.6) Vomiting (11), abdominal pain 
(11), nausea (9),  
Nervous system 
disorders  
24 (11.8) Dizziness (11), headache (7), 
sensory disturbance (3) 
General disorders  22 (10.8) Facial or generalized  edema (11), 
facial flush (4), allergic reaction(3),  
Psychiatric disorders  8  (3.9) Insomnia (4), drug addiction or 
dependence (3), anorexia (1) 
Vision/ Hearing/ 
vestibular disorders  
7  (3.4) Red eye (3), visual disturbance (2), 
eye pain (1), visual field defect (1) 
Cardiovascular disorders  7  (3.4) Palpitation (7) 
Respiratory system 
disorders  
4  (2.0) dyspnea (2), asthma aggravated 
(1), larynx pain (1) 
Urinary system disorders  2  (1.0) Urine discoloration (1), urinary 
retention (1) 
Blood cell/ clotting 
disorders  
2  (1.0) Bruise (1), gingival bleeding (1) 
Reproductive disorders 2  (1.0) Burning feeling vagina (1), 
withdrawal bleeding missed (1) 





Appendix 2.  
World Health Organization-Uppsala Monitoring Centre (WHO-





• Event or laboratory test abnormality, with plausible 
time relationship to drug intake 
• Cannot be explained by disease or other drugs 
• Response to withdrawal plausible 
(pharmacologically, pathologically) 
• Event definitive pharmacologically or 
phenomenologically (i.e. an objective and specific 
medical disorder or a recognized pharmacological 
phenomenon) 
• Rechallenge satisfactory, if necessary 
Probable/ 
Likely 
• Event or laboratory test abnormality, with 
reasonable time relationship to drug intake 
• Unlikely to be attributed to disease or other drugs 
• Response to withdrawal clinically reasonable 
• Rechallenge not required 
Possible 
• Event or laboratory test abnormality, with 
reasonable time relationship to drug intake 
• Could also be explained by disease or other drugs 
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• Information on drug withdrawal may be lacking or 
unclear 
Unlikely 
• Event or laboratory test abnormality, with a time to 
drug intake that makes a relationship improbable 
(but not impossible) 




• Event or laboratory test abnormality 
• More data for proper assessment needed, or 
• Additional data under examination 
Unassessable/ 
Unclassifiable 
• Event or laboratory test abnormality 
• More data for proper assessment needed, or 
• Additional data under examination 
• Report suggesting an adverse reaction 
• Cannot be judged because information is 
insufficient or contradictory 






Appendix 3.  
Classification of clinical manifestations in adverse drug reactions 
according to the World Health Organization-adverse reaction 




Skin and appendages disorders 
Musculo-skeletal system/Collagen disorders 
Central and peripheral/Autonomic nervous system 
disorders 
Vision/Hearing and vestibular/other sense disorders 
Psychiatric disorders 
Gastro-intestinal system disorders 
Liver and biliary system disorders 
Metabolic and nutritional disorders 
Endocrine disorders 
Cardiovascular disorders 
Respiratory system disorders 
Red blood cell/ White cell/Platelet, bleeding and 
clotting disorders 
Urinary system disorders 
Reproductive disorders, male/female 
Foetal disorders 
























Miscellaneous(Application site disorders/ Resistance 










Appendix 4.  
Classification of the causative drugs by the Anatomical Therapeutic 
Chemical classification system 
Code Contents 
A Alimentary tract and metabolism 
B Blood and blood forming organs 
C Cardiovascular system 
D Dermatologicals 
G Genito-urinary system and sex hormones 
H Systemic hormonal preparations, excluding sex hormones 
and insulins 
J Antiinfectives for systemic use 
L Antineoplastic and immunomodulating agents 
M Musculo-skeletal system 
N Nervous system 
P Antiparasitic products, insecticides and repellents 
R Respiratory system 












약물이상반응은 환자의 입원과 치료기간의 연장을 유발하며, 
치료비용을 상승시켜 환자와 보험제정의 경제적 부담을 가중시킨다. 
의료진의 긴밀한 모니터링 하에 있는 입원환자에 비해 외래환자는 
환자의 자발적인 의사표현이 없으면 ADR을 알아내기 어렵고, 그로 
인해 약물이상반응에 대한 대처도 늦어져 위험과 비용이 더욱 
증가할 수 있다.  
지역약국은 전국에 널리 분포되어 있어 환자의 접근이 
편리하며, 약에 관한 상담이 비교적 용이하여, 외래환자의 
약물이상반응을 효과적으로 모니터링하고 상담 및 정보를 제공할 
수 있는 요양기관이다. 대한약사회 지역의약품안전센터는, 2013년 
식품의약품안정처에 의해 전국 지역약국과 외래환자를 대상으로 
약물감시활동을 수행하도록 지역의약품안전센터로 지정되었다.  
그 이전까지 지역의약품안전센터를 통한 자발적인 ADR 보고는 
대부분 입원환자 사례를 중심으로 이루어져왔다. 약물이상반응사례 
분석연구들도 입원환자 사례를 중심으로 이루어져왔으며, 아직까지 
외래환자에서의 자발적 유해사례보고에 대한 연구가 미비한 
실정이다. 지역약국 약사에 의해 보고된 약물이상반응사례에 대한 
분석자료는 외래환자에서의 약물이상반응을 예방하는데 중요한 
정보를 제공할 수 있을 것이다. 또한 개별 연령군을 대상으로 한 
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약물이상반응에 대한 연구들은 있어왔으나, 외래환자에서 보고된 
약물이상반응을 연령군별로 비교 및 분석한 연구는 제한적이다. 
이에 본 연구는 전국 지역약국에서 대한약사회 
지역의약품안전센터에 보고된 약물이상반응사례를 연령군별로 
분석하여, 외래환자에서의 약물이상반응의 양상 및 원인약물들을 
알아보고자 하였다. 
2013년 1월부터 2014년 6월까지 18개월간 지역약국 약사에 
의해 대한약사회 지역의약품안전센터에 보고된 약물이상반응사례를 
대상으로 하였다. 환자의 나이에 따라 소아군(18세 미만), 성인군, 
노인군(65세 이상)으로 분류하여 군별 약물이상반응의 증상과 
원인약물의 보고빈도 및 보고 분율을 비교하였다.  
인과성평가는 World Health Organization-Uppsala Monitoring 
Centre 기준을 근거로 하였다. 약물이상반응 증상과 원인약물의 
분류에는 각각 World Health Organization Adverse Reaction 
Terminology 코드와 Anatomical Therapeutic Chemical Classification 
System 분류 체계를 사용하였다. 
보고된 약물이상반응 42,018건 중 31,398건(74.9%)이 인과관계를 
가졌다. 분석대상 9,705명의 환자의 나이 중앙값은 58.0세였으며 
여성이 66.9%를 차지하였다. 연령군은 성인군 64.0%, 노인군 32.5%, 
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소아군 3.5%로 구성되었다.  
다빈도 약물이상반응 증상은 위장관계(34.4%), 신경계(14.4%), 
정신과계(12.1)로 어지러움(8.5%), 소화불량(8.5%), 졸림(6.3%)의 
보고빈도가 높았다. 약물이상반응 원인약물로는 위산장애관련 
약물(11.4%), 항염증제(10.5%), 진통제(7.2%), 항균제(7.1%)가 높은 
빈도를 보였다. 약물이상반응 증상과 원인약물을 연령군별로 
비교하였을 때, 소아군에서는 설사와 항균제가 다른 군에 비해 높은 
보고분율을 보였다(p<0.001). 노인군에서는 어지럼증을 포함한 
신경계 증상과 비뇨기계 증상이 높게 나타났다(p<0.001).  
중대한 유해사례는 52명의 환자에서 보고되었다. 아나필락시스 
반응(19.7%)이 중대한 유해사례의 주된 증상이었고 비스테로이드성 
항염증제와 세파로스포린계 항균제가 주요 원인약물이었다. 
비처방의약품으로 인한 약물이상반응 612건에서는 
피부증상(29.6%)의 보고빈도가 높았으며, 원인약물로 비스테로이드성 
항염증제의 보고빈도가 높았다.  
지역약국약사에 의해 보고된 외래환자에서의 약물이상반응 
사례에서 위장관계, 신경계, 정신신경계 증상이 보고빈도가 
높았으며, 항염증제, 진통제, 항생제는 다빈도 원인약물이자 중대한 
유해사례의 주요 원인약물이었다. 외래환자에서의 약물이상반응의 
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증상 및 원인약물의 양상은 연령군별로 차이가 있음을 확인하였다. 
따라서, 외래환자의 각 연령군별 특징에 따른 맞춤형 




주요어 : 약물이상반응, 자발적 보고, 지역약국, 외래환자, 연령군,  
약물감시활동 
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